-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ac/yvvGkYrdJf/RU553HvDFmL1kZaCWNhJAEHJtzBCZaTLYVGXG65od6e2aaysgp V+Q+1/fEBaX6JqImcSkclQ== 0000950123-05-008453.txt : 20050713 0000950123-05-008453.hdr.sgml : 20050713 20050713162556 ACCESSION NUMBER: 0000950123-05-008453 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20050713 DATE AS OF CHANGE: 20050713 GROUP MEMBERS: BIOMEDICAL OFFSHORE VALUE FUND, LTD. GROUP MEMBERS: BIOMEDICAL VALUE FUND, L.P. GROUP MEMBERS: DR. JEFFREY R. JAY, M.D. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: V I TECHNOLOGIES INC CENTRAL INDEX KEY: 0001040017 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 113238476 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-55237 FILM NUMBER: 05952584 BUSINESS ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 5167527314 MAIL ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GREAT POINT PARTNERS LLC CENTRAL INDEX KEY: 0001281446 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: 2 PICKWICK PLAZA STREET 2: STE 450 CITY: GREENWICH STATE: CT ZIP: 06830 SC 13D/A 1 y10794a1sc13dza.txt AMENDMENT #1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* V.I. Technologies, Inc. ------------------------------------- (Name of Issuer) Common Stock ------------------------------------- (Title of Class of Securities) 917920 10 0 ------------------------------------- (CUSIP Number) Dr. Jeffrey R. Jay, MD Great Point Partners, LLC 2 Pickwick Plaza, Suite 450 Greenwich, CT 06830 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 8, 2005 ----------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 917920 10 0 Page 2 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Great Point Partners, LLC S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 0 SHARES -------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 7,022,932 OWNED BY -------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 0 REPORTING -------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 7,022,932 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY 7,022,932 OWNED BY EACH REPORTING PERSON - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 16.7%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO CUSIP No. 917920 10 0 Page 3 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Biomedical Value Fund, L.P. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, U.S.A - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 3,720,182 SHARES --------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 0 OWNED BY --------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 3,720,182 REPORTING --------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 0 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY 3,720,182 OWNED BY EACH REPORTING PERSON - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 9.1%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON PN CUSIP No. 917920 10 0 Page 4 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Biomedical Offshore S.S. OR I.R.S. IDENTIFICATION NO. Value Fund, Ltd. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 3,302,750 SHARES -------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 0 OWNED BY -------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 3,302,750 REPORTING -------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 0 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,302,750 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 8.1%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON CO CUSIP No. 917920 10 0 Page 5 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Dr. Jeffrey R. Jay, M.D. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 90,625 SHARES -------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 7,022,932 OWNED BY -------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 90,625 REPORTING -------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 7,022,932 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY 7,113,557 OWNED BY EACH REPORTING PERSON - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 16.9%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON IN * The calculation of the foregoing percentages is based on 39,506,529 shares of Common Stock outstanding as of June 30, 2005, as reported in the Issuer's Form PRE 14A filed with the Securities and Exchange Commission on June 30, 2005. CUSIP No. 917920 10 0 Page 6 of 8 AMENDMENT NO. 1 TO STATEMENT ON SCHEDULE 13D FILED BY GREAT POINT PARTNERS, LLC. This Amendment No. 1 amends and supplements Item 5 of the Schedule 13D, dated March 11, 2005 (the "Schedule 13D") filed by Great Point Partners, LLC ("Great Point"), Biomedical Value Fund, L.P. ("BMVF"), Biomedical Offshore Value Fund, Ltd. ("BOVF") and Dr. Jeffrey R. Jay, M.D. ("Dr. Jay") with respect to the shares of common stock, par value $0.01 per share (the "Common Stock") of V.I. Technologies, Inc. (the "Issuer"). Item 5 "Interest in Securities of the Issuer" of the Schedule 13D is hereby amended to add the following information: Item 5. Interest in Securities of the Issuer. (a) and (b) As a result of sales conducted on July 8, 2005 and July 12, 2005, BMVF is now the beneficial owner of 3,720,182 shares of Common Stock, consisting of 2,332,884 shares of Common Stock and warrants to purchase 1,387,298 shares of Common Stock. Such shares, in the aggregate, represent 9.1% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BMVF disclaims beneficial ownership of any securities owned by BOVF or Dr. Jay. As a result of sales conducted on July 8, 2005 and July 12, 2005, BOVF is now the beneficial owner of 3,302,750 shares of Common Stock, consisting of 2,045,000 shares of Common Stock and warrants to purchase 1,257,750 shares of Common Stock. Such shares, in the aggregate, represent 8.1% of Common Stock outstanding, computed in accordance with Rule 13d-3. BOVF disclaims beneficial ownership of any securities owned by BMVF or Dr. Jay. Great Point is the investment manager of each of BMVF and BOVF, and by virtue of such status has shared voting and investment power with respect to securities owned and held by BMVF and BOVF and may be deemed to be the beneficial owner of such securities. Thus, as a result of the July 8, 2005 and July 12, 2005 sales described above, Great Point may now be deemed to be the beneficial owner of 7,022,932 shares of Common Stock, consisting of 4,377,884 shares of Common Stock and warrants to purchase 2,645,048 shares of Common Stock. Such shares, in the aggregate, represent 16.7% of Common Stock outstanding, computed in accordance with Rule 13d-3. Great Point disclaims beneficial ownership of any securities owned by Dr. Jay Dr. Jay beneficially owns 90,625 shares of Common Stock, consisting of 62,500 shares of Common Stock and warrants to purchase 28,125 shares of Common Stock. In addition, Dr. Jay, as senior managing member of Great Point, has shared voting and investment power with respect to securities owned and held by BMVF and BOVF and may be deemed to be the beneficial owner of such securities. Therefore, as a result of the July 8, 2005 and July 12, 2005 sales described above, Dr. Jay may now be deemed to be the beneficial owner of 7,113,557 shares of Common Stock, consisting of an aggregate amount of 4,440,384 shares of Common Stock and warrants to CUSIP No. 917920 10 0 Page 7 of 8 purchase 2,673,173 shares of Common Stock. Such shares, in the aggregate, represent 16.9% of Common Stock outstanding, computed in accordance with Rule 13d-3. Notwithstanding the above, Great Point and Dr. Jay disclaim beneficial ownership of the shares of Common Stock held by BMVF and BOVF, except to the extent of any pecuniary interest, and this Amendment No. 1 to the Schedule 13D shall not be deemed to be an admission that they are the beneficial owners of such securities. (c) The tables below set forth information with respect to all sales of Common Stock by each of BMVF and BOVF during the last 60 days. All of such sales were executed through broker's transactions on NASDAQ. BMVF:
TRANSACTION DATE NUMBER OF SHARES PRICE PER SHARE - ---------------- ---------------- --------------- July 8, 2005 600,000 $ 5.25 July 12, 2005 300,000 $ 5.50
BOVF:
TRANSACTION DATE NUMBER OF SHARES PRICE PER SHARE - ---------------- ---------------- --------------- July 8, 2005 600,000 $ 5.25 July 12, 2005 300,000 $ 5.50
Item 7. Materials to be Filed as Exhibits Exhibit E: Joint Filing Agreement among Great Point, BMVF, BOVF and Dr. Jay, dated July 13, 2005. Except as expressly amended and supplemented hereby, the text of the Schedule 13D remains in effect without any further modification. CUSIP No. 917920 10 0 Page 8 of 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to the undersigned is true, complete and correct. Dated: July 13, 2005 GREAT POINT PARTNERS, LLC /s/ Dr. Jeffrey R. Jay, M.D. ------------------------------------- By Dr. Jeffrey R. Jay, M.D., as senior managing member BIOMEDICAL VALUE FUND, L.P. /s/ Dr. Jeffrey R. Jay, M.D. ----------------------------------- By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay as senior managing member BIOMEDICAL OFFSHORE VALUE FUND, Ltd. /s/ Dr. Jeffrey R. Jay, M.D. ----------------------------------- By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay, M.D., as senior managing member DR. JEFFREY R. JAY, M.D. /s/ Dr. Jeffrey R. Jay, M.D. ----------------------------------- EX-99.E 2 y10794a1exv99we.txt JOINT FILING AGREEMENT Exhibit E JOINT FILING STATEMENT The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D Amendment to which this Exhibit is attached, and such Schedule 13D Amendment is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Date: July 13, 2005 GREAT POINT PARTNERS LLC Signature: /s/ Dr. Jeffrey R. Jay, M.D. ---------------------------------- By Dr. Jeffrey R. Jay, M.D., as senior managing member BIOMEDICAL VALUE FUND L.P. Signature: /s/ Dr. Jeffrey R. Jay, M.D. ---------------------------------- By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay, M.D., as senior managing member BIOMEDICAL OFFSHORE VALUE FUND, LTD. Signature: /s/ Dr. Jeffrey R. Jay, M.D. ---------------------------------- By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay, M.D., as senior managing member DR. JEFFREY R. JAY, M.D. Signature: /s/ Dr. Jeffrey R. Jay, M.D. ---------------------------------- -----END PRIVACY-ENHANCED MESSAGE-----